Jiangsu (SH:688426) Xin Lang Cai Jing·2025-09-12 10:41Core Viewpoint - 康为世纪 reported a revenue of 87.12 million yuan for the first half of the year, a year-on-year increase of 29.74%, but faced a net loss of 55.91 million yuan, a decrease of 11.70% compared to the previous year, indicating a "revenue growth without profit increase" situation [1][3]. Financial Performance - Revenue for the first half of the year was 87.12 million yuan, up 29.74% year-on-year [1]. - Net profit attributable to shareholders was -55.91 million yuan, down 11.70% year-on-year [1]. - Basic earnings per share were -0.508 yuan, and diluted earnings per share were -0.507 yuan [3]. - The weighted average return on net assets was -3.90%, and the return on net assets after deducting non-recurring gains and losses was -4.64% [3]. - R&D expenses accounted for 46.84% of revenue, down from 68.53% year-on-year [3]. Business Challenges and Strategies - The decline in net profit is attributed to the new technology service business being in a ramp-up phase, leading to higher operating costs than revenue growth [1][4]. - 康为世纪's core products include molecular detection reagents and diagnostic kits, with a focus on the Helicobacter pylori detection kit as a key growth driver [4][5]. - The company is expanding its technology service sector, including gene sequencing and synthesis services, to improve profitability [6]. Market Potential - The market for Helicobacter pylori detection products is projected to reach a sales peak of 1.5 billion yuan by 2030, driven by the need for antibiotic resistance testing [5]. - 康为世纪 is actively working on expanding distribution channels, including partnerships with hospitals and online platforms, to enhance market penetration [5][6]. Financial Position - As of mid-year, the company's cash reserves were 160 million yuan, down 63.39% from 437 million yuan year-on-year [6]. - Accounts receivable amounted to 59.38 million yuan, representing 47.18% of total revenue, with a growth rate exceeding that of revenue [6][7]. - R&D expenses decreased by 11.32% to 41 million yuan, and the number of R&D personnel reduced from 229 to 148 [7].